Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCLX 
Scilex Holding Company (SCLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SCLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $490
1 Year Target Price $490
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.06% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.54M USD | Price to earnings Ratio - | 1Y Target Price 490 |
Price to earnings Ratio - | 1Y Target Price 490 | ||
Volume (30-day avg) 2 | Beta 1.38 | 52 Weeks Range 3.60 - 39.90 | Updated Date 10/17/2025 |
52 Weeks Range 3.60 - 39.90 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -179.12% | Operating Margin (TTM) -206.27% |
Management Effectiveness
Return on Assets (TTM) -65.79% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 5.58 | Enterprise Value 166164743 | Price to Sales(TTM) 2.23 |
Enterprise Value 166164743 | Price to Sales(TTM) 2.23 | ||
Enterprise Value to Revenue 3.76 | Enterprise Value to EBITDA -2.64 | Shares Outstanding 7406210 | Shares Floating 3113582 |
Shares Outstanding 7406210 | Shares Floating 3113582 | ||
Percent Insiders 20.13 | Percent Institutions 73.37 |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid pain management products. It was founded to address the opioid crisis by offering alternative pain relief options. The company's history includes strategic acquisitions and development partnerships to expand its product portfolio.
Core Business Areas
- Non-Opioid Pain Management: Development and commercialization of non-opioid pain management products for acute and chronic pain.
- Neuropathic Pain: Focus on treatments for neuropathic pain conditions, including pain associated with diabetic neuropathy and sciatica.
- Product Development: Research and development of novel pain management therapies.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives with expertise in drug development, regulatory affairs, and commercialization. The organizational structure includes departments for research and development, clinical operations, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- ZTlido: A lidocaine topical system for the treatment of post-herpetic neuralgia (PHN). Market share data unavailable but competes with other topical lidocaine products. Competitors include Teva Pharmaceutical Industries, Mylan (now Viatris).
- Elysium: Under development, a non-opioid treatment for acute pain. It aims to replace opioid use in the pain treatment paradigm. Competitors are all existing opioid medications, as well as other emerging non-opioid pain therapeutics from companies like Pacira BioSciences.
Market Dynamics
Industry Overview
The pain management market is large and growing, driven by the increasing prevalence of chronic pain conditions and the opioid crisis. There is a growing demand for non-opioid pain management options.
Positioning
Scilex Holding Company is positioned as a leader in the development and commercialization of non-opioid pain management products. Its competitive advantage lies in its focus on innovative non-opioid therapies.
Total Addressable Market (TAM)
The global pain management market is estimated at over $80 billion. Scilex Holding Company is positioned to capture a portion of this TAM with its non-opioid pain management products.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- Innovative product pipeline
- Experienced management team
Weaknesses
- Limited product portfolio
- Dependence on key products
- Relatively small market capitalization
Opportunities
- Expanding pain management market
- Increasing demand for non-opioid therapies
- Potential for strategic partnerships and acquisitions
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- VRX
- TEVA
- MYL
Competitive Landscape
Scilex Holding Company competes with larger pharmaceutical companies. Its advantage is in specialized non-opioid pain treatments but faces financial competition from bigger competitors.
Major Acquisitions
Sorrento Therapeutics
- Year: 2022
- Acquisition Price (USD millions): 0
- Strategic Rationale: Scilex Holding Company was created as a subsidiary of Sorrento Therapeutics to address the non-opioid pain market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in past revenue and product development progress.
Future Projections: Future growth depends on successful product development, regulatory approvals, and commercialization.
Recent Initiatives: Recent initiatives include development programs, regulatory submissions, and marketing efforts.
Summary
Scilex Holding Company is a biopharmaceutical company focused on non-opioid pain management. They have a small but focused product pipeline and compete with larger companies. They face competitive challenges due to their size and financial limitations but have opportunities in the growing market for non-opioid pain therapies. The successful commercialization of new drugs is vital for the company's future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may not be precise. Financial data may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-05 | CEO, President & Executive Chairman Dr. Henry H. Ji Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 31 | Website https://www.scilexholding.com |
Full time employees 31 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.